Novo Nordisk A/S (NVO)
GPW
Closed
Aug 24, 2026
Day's Range
171.6652 wk Range
129.26Overview - NVO - Novo Nordisk A/S
Key Statistics
Valuation
Enterprise Value
484.76B
P/E (Trailing)
‪10.78‬
PEG Ratio
‪-0.52‬
Price / Sales (TTM)
‪2.25‬
Price / Book
‪3.36‬
EV / EBITDA
‪4.84‬
Profitability
Gross Margin
‪78.21%‬
Profit Margin
‪35.34%‬
Operating Margin
‪42.54%‬
Return on Assets
‪18.72%‬
Return on Equity
‪59.81%‬
Ownership
Shares Outstanding
4.42B
Float
3.17B
Held by Insiders
‪5.28%‬
Held by Institutions
‪33.32%‬
Price stats
Beta
‪0.34‬
50-Day Avg
‪179.05‬
200-Day Avg
‪171.05‬
Dividends
Payout Ratio
‪58.84%‬
Frequency
Semi-Annual
Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - NVO - Novo Nordisk A/S
Peers - NVO - Novo Nordisk A/S
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on GPW.
- NVOGPWNovo Nordisk A/S744.41BMarket Cap-26.23%52-week change10.78P/E (Trailing)‪35.34%‬Profit Margin
- LILYGPWEli Lilly and Company4.13TMarket Cap+22.74%52-week change42.02P/E (Trailing)‪33.52%‬Profit Margin
- SANGPWBanco Santander, S.A.787.37BMarket Cap+34.93%52-week change14.14P/E (Trailing)‪33.46%‬Profit Margin
- BAYGPWBayer AG208.66BMarket Cap+42.45%52-week change27.93P/E (Trailing)‪-3.83%‬Profit Margin
Profile Summary - NVO - Novo Nordisk A/S
About
Novo Nordisk A/S is a global pharmaceutical company specializing in research, development, and manufacturing of treatments for serious chronic diseases. Founded through the 1989 merger of Danish insulin pioneers Nordisk Insulaboratorium and Novo Terapeutisk Laboratorium, it traces its roots to 1923 when commercial…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
